dc.date.accessioned | 2024-02-09T18:00:12Z | |
dc.date.available | 2024-02-09T18:00:12Z | |
dc.date.created | 2023-08-08T15:27:01Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Lindemann, Kristina Yvonne Kathe Danbolt, Svana Ramberg, Lene Kristine Marsby Eyjólfsdóttir, Brynhildur Wang, Yun Heli-Haugestøl, Anne Gjertine Walcott, Sara Mjåland, Odd Navestad, Gerd Hermanrud, Silje Juul-Hansen, Knut Erling Bragstad, Line Kildal Opheim, Randi Kleppe, Andreas Kongsgaard, Ulf Erik . Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients. International Journal of Gynecological Cancer. 2023, 33(8), 1287-1294 | |
dc.identifier.uri | http://hdl.handle.net/10852/107773 | |
dc.description.abstract | Objectives This study aimed to analyze the adherence to strategies to prevent post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) protocol for gynae-oncology patients. Patient-reported nausea before and after ERAS was also studied. Methods This prospective observational study included all patients undergoing laparotomy for a suspicious pelvic mass or confirmed advanced ovarian cancer before (pre-ERAS) and after the implementation of ERAS (post-ERAS) at Oslo University Hospital, Norway. Patients were a priori stratified according to the planned extent of surgery into two cohorts (Cohort 1: Surgery of advanced disease; Cohort 2: Surgery for a suspicious pelvic tumor). Clinical data including baseline characteristics and outcome data were prospectively collected. Results A total of 439 patients were included, 243 pre-ERAS and 196 post-ERAS. At baseline, 27% of the patients reported any grade of nausea. In the post-ERAS cohort, statistically significantly more patients received double post-operative nausea and vomiting prophylaxis (64% pre-ERAS vs 84% post-ERAS, p<0.0001). There was no difference in the need for rescue medication (82% pre-ERAS vs 79% post-ERAS; p=0.17) and no statistically significant difference between pre- and post-ERAS or between the surgical cohorts in patient-reported nausea of any grade on day 2. Patients who reported none/mild nausea on day 2 had significantly less peri-operative fluid administered during surgery than those who reported moderate or severe nausea (median 12.5 mL/kg/hour vs 16.5 mL/kg/hour, p=0.045) but, in multivariable analysis, fluid management did not remain significantly associated with nausea. Conclusion Implementation of an ERAS protocol increased the adherence to post-operative nausea and vomiting prevention guidelines. Nausea, both before and after laparotomy, remains an unmet clinical need of gynae-oncology patients also in an ERAS program. Patient-reported outcome measures warrant further investigation in the evaluation of ERAS. | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.title | Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients | |
dc.title.alternative | ENEngelskEnglishPatient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients | |
dc.type | Journal article | |
dc.creator.author | Lindemann, Kristina Yvonne Kathe | |
dc.creator.author | Danbolt, Svana | |
dc.creator.author | Ramberg, Lene Kristine Marsby | |
dc.creator.author | Eyjólfsdóttir, Brynhildur | |
dc.creator.author | Wang, Yun | |
dc.creator.author | Heli-Haugestøl, Anne Gjertine | |
dc.creator.author | Walcott, Sara | |
dc.creator.author | Mjåland, Odd | |
dc.creator.author | Navestad, Gerd | |
dc.creator.author | Hermanrud, Silje | |
dc.creator.author | Juul-Hansen, Knut Erling | |
dc.creator.author | Bragstad, Line Kildal | |
dc.creator.author | Opheim, Randi | |
dc.creator.author | Kleppe, Andreas | |
dc.creator.author | Kongsgaard, Ulf Erik | |
cristin.unitcode | 185,53,49,14 | |
cristin.unitname | Avdeling for gynekologisk kreft | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2165696 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Gynecological Cancer&rft.volume=33&rft.spage=1287&rft.date=2023 | |
dc.identifier.jtitle | International Journal of Gynecological Cancer | |
dc.identifier.volume | 33 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | 1287 | |
dc.identifier.endpage | 1294 | |
dc.identifier.doi | https://doi.org/10.1136/ijgc-2023-004356 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1048-891X | |
dc.type.version | PublishedVersion | |